DAFNA Capital Trims Axogen Stake Following 71% Rally and 20% Revenue Growth

DAFNA Capital Management's decision to trim its stake in Axogen (AXGN) by roughly 26% of its position highlights a classic portfolio rebalancing act in the high-growth biotech and medical device sector. The sale of 265,456 shares, valued at approximately $6.53 million, comes at a time when Axogen has significantly outperformed the broader market. With a 71% gain over the last year, compared to the S&P 500's 15% rise, the stock has reached a valuation where institutional investors often look to lock in gains. This move, disclosed in a February 2026 SEC filing, reflects a disciplined approach to risk management rather than a shift in the underlying thesis for the peripheral nerve repair market.

Axogen’s ascent is rooted in its dominant position within the peripheral nerve repair market. The company’s 20% revenue growth is a testament to the increasing adoption of its biological grafts, specifically the Avance Nerve Graft. Unlike traditional nerve repair methods that often rely on autografts—harvesting a nerve from the patient's own body, which causes secondary site morbidity—Axogen’s processed human nerve allograft provides a ready-to-use alternative that maintains the natural structure of the nerve. This clinical advantage has allowed Axogen to capture significant market share in trauma and reconstructive surgeries, particularly in hand and orthopedic procedures.

“

The sale of 265,456 shares, valued at approximately $6.53 million, comes at a time when Axogen has significantly outperformed the broader market.

The company’s product portfolio extends beyond simple grafts to include a comprehensive suite of nerve protection and connection tools. The AxoGuard Nerve Connector and Protector, along with the AxoGuard Nerve Cap, provide surgeons with a versatile toolkit for managing nerve injuries and preventing the formation of painful neuromas. Furthermore, the Avive Soft Tissue Membrane has expanded Axogen's reach into soft tissue protection, while the AxoTouch two-point discriminator offers a standardized method for post-operative sensory monitoring. This integrated ecosystem creates a high barrier to entry for competitors and fosters strong loyalty among surgical specialists.

DAFNA’s broader portfolio strategy provides additional context for the Axogen trim. The fund remains heavily invested in high-conviction biotech plays, with Revolution Medicines (RVMD) serving as its largest holding at 11.33% of assets under management. Revolution Medicines, which focuses on RAS-addicted cancers, represents a different risk-reward profile than the more established medical device business of Axogen. By rotating capital from a 71% winner like Axogen into other top holdings like Cytokinetics (CYTK) and AtriCure (ATRC), DAFNA is likely seeking to maintain its target exposure levels while capitalizing on the relative value of its other core positions.